CPA
IONS icon

Capital Performance Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Capital Performance Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$40.1K – 1371
2024
Q3 		$40.1K Buy
+1,000
New +$46.5K 0.01% 411

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Capital Performance Advisors's IONS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 1,000 shares — an estimated $40.1K sold.

Capital Performance Advisors first reported a position in IONS in Q3 2024 and held it in 1 quarter. The position peaked at $40.1K in Q3 2024. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1,000 Ionis Pharmaceuticals shares in Q4 2024, an estimated $40.1K.
  • Capital Performance Advisors first reported a position in Ionis Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Ionis Pharmaceuticals position peaked at $40.1K in Q3 2024.
  • 354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.